Tempus AI’s TEM reimbursement showed modest sequential improvement in the third quarter of 2025, though average blended reimbursement per test continues to lag peers by a meaningful margin. The ...

An update from BioMark Diagnostics ( ($TSE:BUX) ) is now available. BioMark Diagnostics Inc. has begun the process to obtain ISO 15189 ...

Approaches incorporating rapid or digital PCR, CRISPR, syndromic testing, and multimodal systems reached new milestones this year.

Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the ...

Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...

Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...

According to the USDA, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) ...

EFLM recognizes Babson Diagnostics for innovations in sample collection and preparation ...

Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

Next-gen diagnostics: Advances in molecular platforms, informatics and AI enable smarter, more personalized care. Innovation at scale: R&D strategies are shaping diagnostics to meet global healthcare ...

At the end of 2025, Microbix’s current ratio (current assets divided by current liabilities) was 8.48 and its debt to equity ...

A rapid, user-friendly, highly accurate sensitive molecular test has been developed for diagnosing hepatitis C virus (HCV).